G1 Therapeutics Inc Stock Price, News & Analysis

COSELA Added to NCCN Guidelines

G1 Therapeutics (GTHX) announced that its drug, COSELA™ (trilaciclib), has been included in the updated National Comprehensive Cancer Network (NCCN) Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors. This inclusion underscores COSELA's significance in cancer management, particularly for those undergoing chemotherapy for extensive-stage small cell lung cancer (ES-SCLC). COSELA is the first proactive multilineage myeloprotection agent aimed at reducing chemotherapy-induced myelosuppression.

On March 5, 2021, G1 Therapeutics, Inc. (GTHX) announced the grant of inducement stock options totaling 14,300 shares to two new employees under its 2021 Inducement Equity Incentive Plan. These options, exercisable at $23.07 per share, are part of the strategy to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with a quarter vesting annually, subject to employment conditions. G1 Therapeutics focuses on developing next-generation cancer therapies and is based in Research Triangle Park, N.C.

G1 Therapeutics (Nasdaq: GTHX) announced its participation in two upcoming investor conferences. CEO Jack Bailey will present at the HC Wainwright Global Life Sciences Conference starting March 9, 2021, at 7:00 AM ET. He will also engage in a fireside chat at the Roth 33rd Annual Conference on March 17, 2021, at 10:30 AM ET. Both conferences are virtual, and webcasts can be accessed via the company's website.

G1 Therapeutics focuses on developing therapies to improve cancer treatment, including its product COSELA™.

G1 Therapeutics and Boehringer Ingelheim announce the U.S. launch of COSELA™ (trilaciclib), FDA approved for myeloprotection in extensive-stage small cell lung cancer (ES-SCLC). This innovative therapy is the first to reduce chemotherapy-induced myelosuppression. Patients can access COSELA through specialty distributors and will be supported by the G1 to One™ Patient Support Program, designed to help with coverage and affordability. Approximately 30,000 cases of SCLC are treated annually in the U.S., emphasizing the need for effective treatment options.

G1 Therapeutics (GTHX) announced the FDA approval of COSELA™ (trilaciclib) as the first therapy for reducing chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer. Commercial availability is expected in early March 2021. The company plans to initiate three additional clinical trials in the first half of 2021, exploring COSELA's efficacy across multiple cancer types.

Q4 2020 financials revealed a net loss of $25.3 million, down from $35.4 million in Q4 2019, with cash and equivalents totaling $207.3 million.

G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on February 24, 2021, at 4:30 p.m. ET to provide a corporate and financial update for Q4 2020 and the full year. Interested parties can join by dialing (866) 763-6020 for domestic calls or (210) 874-7713 for international calls, using conference code 5267698. The event will be accessible via the company’s Events & Presentations page. G1 Therapeutics focuses on developing therapies for cancer, including its product COSELA™ (trilaciclib) and has a pipeline for various solid tumors.

G1 Therapeutics announced FDA approval for COSELA (trilaciclib), the first therapy to offer myeloprotection for patients with extensive-stage small cell lung cancer (ES-SCLC) undergoing chemotherapy. This innovative treatment reduces the incidence and duration of severe neutropenia and related complications, enhancing patient quality of life. COSELA will be available through specialty distributors in early March 2021. Clinical trials demonstrated significant reductions in myelosuppression-related issues. Post-marketing studies will follow to monitor COSELA's long-term impact.

G1 Therapeutics (Nasdaq: GTHX) announced that CEO Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference on February 11, 2021, at 2:00 PM ET. This virtual event will feature a fireside chat, accessible via a live webcast. G1 Therapeutics is focused on developing innovative cancer therapies, including Trilaciclib, which has received Breakthrough Therapy Designation and is under FDA review with a PDUFA date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.

G1 Therapeutics, a clinical-stage oncology company, announced that CEO Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. ET. The presentation will be accessible via a live and archived webcast on the company’s events page. G1 Therapeutics focuses on developing therapies to improve cancer treatment outcomes, including Trilaciclib, which is under FDA review with a PDUFA action date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.